

18 November 2021

ASX Announcement

Notice under Section 708A of the Corporations Act

This notice is given by Island Pharmaceuticals Ltd (**Issuer**) under section 708A(5)(3) of the Corporations Act 2001 (Cth) (**Act**).

The issuer on 18 November 2021 issued 300,000 shares at an issue price of \$0.25 per share following shareholder approval at the Company's annual general meeting held on 17 November 2021 to issue shares to three Directors in lieu of Directors' fees (the **Issued Shares**).

Pursuant to section 708A(5)(e) of the Act, the Issuer gives notice that:

- (a) the Issued Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this notice, the Issuer has complied with:
 - i. the provisions of Chapter 2M of the Act, as they apply to the Issue; and
 - ii. section 674 of the Act; and
- (c) as at the date of this notice, there is no information that is 'excluded information' within the meaning of sections 708A(7) and 708A(8) of the Act.

ENDS

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Isla Pharmaceuticals
info@islandpharmaceuticals.com

For further information, please contact:

<p>Investors: Jane Lowe IR Department Mobile: +61 411 117 774 jane.lowe@irdepartment.com.au</p>	<p>Media: Juliana Roadley IR Department Mobile: +61 414 889 863 juliana.roadley@irdepartment.com.au</p>
---	---

About Island Pharmaceuticals

Island is clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The Company is advancing toward a Phase II clinical trial in dengue-infected subjects.



If ISLA-101 achieves FDA approval, and certain other criteria are met, Isla may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) would permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.